 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...112113114115116117118119120121122...143144» |
- ||| Biomarker, Enrollment change, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Sep 1, 2017
P2, N=1400, Recruiting, Sponsor: Hoffmann-La Roche
N=610 --> 1400 | Trial primary completion date: Feb 2019 --> Oct 2020
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer. (Pubmed Central) - Aug 24, 2017
The short overall treatment time and low rates of acute toxicity make SBRT an optimal vehicle to integrate with novel systemic therapies, and several phase II studies have used concurrent cetuximab as a radiosensitizer with SBRT with promising results. Ongoing studies aim to evaluate the potential synergistic effect of SBRT with immune checkpoint inhibitors in recurrent head and neck cancer.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma. (Pubmed Central) - Aug 24, 2017
CP is well tolerated in this population of patients, with favorable tumor efficacy. First-line use and an ECOG 0 of 1 points appears to confer superior outcomes.
- || patritumab (U3-1287) / Amgen, Daiichi Sankyo
Trial primary completion date, Combination therapy, Metastases: Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN ) (clinicaltrials.gov) - Aug 24, 2017
P2, N=87, Active, not recruiting, Sponsor: Daiichi Sankyo, Inc.
First-line use and an ECOG 0 of 1 points appears to confer superior outcomes. Trial primary completion date: Jul 2017 --> Oct 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Imfinzi (durvalumab) / AstraZeneca
New P2/3 trial, PD(L)-1 Biomarker, Metastases: NRG-HN004: Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin (clinicaltrials.gov) - Aug 22, 2017
P2/3, N=533, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial primary completion date, Surgery, Metastases: Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 22, 2017
P2, N=79, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2017 --> Oct 2017 Trial primary completion date: Dec 2017 --> May 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: EAGLE: Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (clinicaltrials.gov) - Aug 21, 2017
P2/3, N=243, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial primary completion date: Dec 2017 --> May 2017 Trial primary completion date: Dec 2016 --> Oct 2014
- | CDX-3379 / Celldex
New P2 trial, Combination therapy, Metastases: A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Aug 21, 2017
P2, N=30, Not yet recruiting, Sponsor: Celldex Therapeutics
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC) (clinicaltrials.gov) - Aug 16, 2017
P2, N=33, Completed, Sponsor: Hong Kong Nasopharyngeal Cancer Study Group Limited
Trial primary completion date: Dec 2016 --> Oct 2014 Active, not recruiting --> Completed
- | New P2 trial, Metastases: Tumorspheres Colrec: Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 15, 2017
P2, N=90, Not yet recruiting, Sponsor: Vejle Hospital
- | Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. (Pubmed Central) - Aug 12, 2017
Median progression-free survival was 2.1 months, and median overall survival was 8 months. Conclusion Pembrolizumab exhibited clinically meaningful antitumor activity and an acceptable safety profile in recurrent/metastatic head and neck squamous cell carcinoma previously treated with platinum and cetuximab.
- | Trial primary completion date, Combination therapy: Bevacizumab in Multiple Phase I Combinations (clinicaltrials.gov) - Aug 11, 2017
P1, N=354, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Conclusion Pembrolizumab exhibited clinically meaningful antitumor activity and an acceptable safety profile in recurrent/metastatic head and neck squamous cell carcinoma previously treated with platinum and cetuximab. Trial primary completion date: Oct 2017 --> Oct 2019
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. (Pubmed Central) - Aug 9, 2017
The lung V5 was not associated with any ≥ grade 3 toxicity, whereas the lung V20 was associated with increased ≥ grade 3 pneumonitis risk on multivariable analysis ( P = .026). Conclusion IMRT was associated with lower rates of severe pneumonitis and cardiac doses in NRG Oncology clinical trial RTOG 0617, which supports routine use of IMRT for locally advanced NSCLC.
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Combination therapy, Metastases: Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial. (clinicaltrials.gov) - Aug 9, 2017
P2, N=43, Recruiting, Sponsor: AIO-Studien-gGmbH
Conclusion IMRT was associated with lower rates of severe pneumonitis and cardiac doses in NRG Oncology clinical trial RTOG 0617, which supports routine use of IMRT for locally advanced NSCLC. Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. (Pubmed Central) - Aug 5, 2017
Conclusion HIV-associated SCCAC is potentially curable with definitive CRT. Although addition of cetuximab may result in less LRF, the 20% recurrence and 26% grade 4 toxicity rates indicate the continued need for more-effective and less-toxic therapies.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). (Pubmed Central) - Aug 5, 2017
Grade 4 toxicity occurred in 32%, and 5% had treatment-associated deaths. Conclusion Although the addition of cetuximab to chemoradiation for SCCAC was associated with lower LRF rates than historical data with CRT alone, toxicity was substantial, and LRF still occurs in approximately 20%, indicating the continued need for more effective and less toxic therapies.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Combining Chk1/2 inhibition with cetuximab and radiation enhances in vitro and in vivo cytotoxicity in head and neck squamous cell carcinoma. (Pubmed Central) - Aug 3, 2017
P1b
Taken together, the combination of CHKi with cetuximab plus irradiation displayed significant antitumor effects to HNSCCs both in vitro and in vivo, suggesting this combination therapy may increase clinical benefit. A clinical trial to test this treatment for patients with head and neck cancer is currently ongoing (NCT02555644).
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: IMPACT-CRC: Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 2, 2017
P1/2, N=85, Recruiting, Sponsor: VU University Medical Center
A clinical trial to test this treatment for patients with head and neck cancer is currently ongoing (NCT02555644). Trial primary completion date: Apr 2017 --> Dec 2017
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: ATOM: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Aug 2, 2017
P2, N=122, Completed, Sponsor: EPS Corporation
Trial primary completion date: Apr 2017 --> Dec 2017 Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Trial completion: ATOM ES: Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - Aug 2, 2017
P=N/A, N=110, Completed, Sponsor: EPS Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Circulating tumor cells, Tumor cell, Metastases: VISNU-2: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (clinicaltrials.gov) - Aug 1, 2017
P2, N=240, Active, not recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Nov 2018
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial. (Pubmed Central) - Jul 29, 2017
Trial primary completion date: Jun 2017 --> Nov 2018 Regardless of p16 status, the addition of cetuximab to RT did not alter the incidence, time to onset, severity, or duration of mucositis and dysphagia and did not impact the frequency of feeding tube use.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. (Pubmed Central) - Jul 29, 2017
In combination with cetuximab, ECF and FOLFOX had similar efficacy, but FOLFOX was better tolerated. Although differences were nonsignificant, IC plus cetuximab seemed to be the least effective and most toxic of the three regimens tested.
- Tabrecta (capmatinib) / Incyte, Novartis
Phase classification, Combination therapy: Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy (clinicaltrials.gov) - Jul 28, 2017
P1, N=13, Terminated, Sponsor: Novartis Pharmaceuticals
Although differences were nonsignificant, IC plus cetuximab seemed to be the least effective and most toxic of the three regimens tested. Phase classification: P1/2 --> P1
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date, Monotherapy, Metastases: PIK-ORL: Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive (clinicaltrials.gov) - Jul 26, 2017
P2, N=70, Recruiting, Sponsor: Centre Leon Berard
Phase classification: P1/2 --> P1 Trial primary completion date: Mar 2017 --> Mar 2018
- Tabrecta (capmatinib) / Incyte, Novartis
Trial termination, Trial primary completion date, Combination therapy: Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy (clinicaltrials.gov) - Jul 25, 2017
P1/2, N=13, Terminated, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2017 --> Mar 2018 Suspended --> Terminated | Trial primary completion date: May 2017 --> Jan 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Trial primary completion date: SAKK 16/08: Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jul 25, 2017
P2, N=69, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Suspended --> Terminated | Trial primary completion date: May 2017 --> Jan 2017 Initiation date: Jan 2010 --> May 2010 | Trial primary completion date: Jan 2016 --> Dec 2016
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Surgery: Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jul 25, 2017
P2, N=59, Active, not recruiting, Sponsor: Dwight Heron
Initiation date: Jan 2010 --> May 2010 | Trial primary completion date: Jan 2016 --> Dec 2016 Trial primary completion date: Dec 2016 --> Dec 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Stivarga (regorafenib) / Bayer
Enrollment closed, Enrollment change, Metastases: Regorafenib and Cetuximab in Patients With Advanced Malignancy (clinicaltrials.gov) - Jul 21, 2017
P1, N=39, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting | N=83 --> 39
- || Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Trial primary completion date, Metastases: Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 19, 2017
P1/2, N=150, Active, not recruiting, Sponsor: Array BioPharma
Recruiting --> Active, not recruiting | N=83 --> 39 Trial primary completion date: Jul 2017 --> Oct 2015
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History (clinicaltrials.gov) - Jul 19, 2017
P1, N=16, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Jul 2017 --> Oct 2015 Initiation date: Jul 2012 --> Oct 2012 | Trial primary completion date: Jul 2017 --> Nov 2017
- | Biomarker, Journal: Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. (Pubmed Central) - Jul 19, 2017
Other treatment strategies for LA SCCHN include targeting downstream effectors of signaling and resistance mechanisms to EGFR inhibitors (eg, mammalian target of rapamycin, Src family, and Aurora kinase family). Data from ongoing and future clinical trials will continue to refine current treatment paradigms for LA SCCHN and provide new therapeutic options and potential predictive biomarkers to improve patient efficacy and safety and abrogate resistance.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, WNT974 / Novartis, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Trial primary completion date, Combination therapy, Metastases: Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations (clinicaltrials.gov) - Jul 18, 2017
P1/2, N=60, Active, not recruiting, Sponsor: Array BioPharma
Data from ongoing and future clinical trials will continue to refine current treatment paradigms for LA SCCHN and provide new therapeutic options and potential predictive biomarkers to improve patient efficacy and safety and abrogate resistance. Trial primary completion date: Jun 2017 --> May 2016
- | Opdivo (nivolumab) / BMS
Phase classification, Metastases: Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer (clinicaltrials.gov) - Jul 17, 2017
P1, N=120, Recruiting, Sponsor: RTOG Foundation, Inc.
Trial primary completion date: Jun 2017 --> May 2016 Phase classification: P3 --> P1
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617. (Pubmed Central) - Jul 15, 2017
Phase classification: P3 --> P1 Treatment at institutions with higher clinical trial accrual volume is associated with longer OS among patients with LA-NSCLC participating in a phase III trial.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. (Pubmed Central) - Jul 15, 2017
The p16-positive OPC patients had significantly higher QOL/PS than did p16-negative patients. Pretreatment QOL/PS is a significant independent predictor of outcome in locally advanced HNC.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. (Pubmed Central) - Jul 15, 2017
P3
Among patients with KRAS wt untreated advanced or metastatic colorectal cancer, there was no significant difference in overall survival between the addition of cetuximab vs bevacizumab to chemotherapy as initial biologic treatment. clinicaltrials.gov identifier: NCT00265850.
- tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial primary completion date: An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols (clinicaltrials.gov) - Jul 13, 2017
P1/2, N=50, Enrolling by invitation, Sponsor: ArQule
clinicaltrials.gov identifier: NCT00265850. Trial primary completion date: Jun 2017 --> Dec 2017
- || napabucasin (BBI608) / Sumitomo Pharma
Trial primary completion date, Metastases: A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Jul 13, 2017
P2, N=150, Recruiting, Sponsor: Boston Biomedical, Inc
Trial primary completion date: Jun 2017 --> Dec 2017 Trial primary completion date: Jun 2017 --> Dec 2017
- | Imprime PGG (odetiglucan) / HiberCell
Enrollment change, Combination therapy: PRIMUS: Study of Imprime PGG (clinicaltrials.gov) - Jul 13, 2017
P3, N=217, Terminated, Sponsor: Biothera
Trial primary completion date: Jun 2017 --> Dec 2017 N=795 --> 217
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Combination therapy, Metastases: Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck (clinicaltrials.gov) - Jul 12, 2017
P1/2, N=29, Terminated, Sponsor: Dana-Farber Cancer Institute
N=795 --> 217 Active, not recruiting --> Terminated; The study did not continue to phase II due to the importance of HPV status as a prognostic factor to guide treatment decisions.
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Enrollment open, Enrollment change, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 11, 2017
P1, N=35, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; The study did not continue to phase II due to the importance of HPV status as a prognostic factor to guide treatment decisions. Active, not recruiting --> Recruiting | N=46 --> 35
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial. (Pubmed Central) - Jul 9, 2017
P3
Active, not recruiting --> Recruiting | N=46 --> 35 The results of a possible cetuximab-related laryngeal preservation benefit for patients with hypopharyngeal or laryngeal cancer are intriguing; these results need to be interpreted in the context of a retrospective subset analysis with limited sample size.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial primary completion date, Metastases: Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). (clinicaltrials.gov) - Jul 7, 2017
P2, N=27, Completed, Sponsor: Gruppo Oncologico del Nord-Ovest
The results of a possible cetuximab-related laryngeal preservation benefit for patients with hypopharyngeal or laryngeal cancer are intriguing; these results need to be interpreted in the context of a retrospective subset analysis with limited sample size. Recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jun 2017
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. (Pubmed Central) - Jul 5, 2017
This observation was noted mainly in p16-negative patients. Grade 2 to 4 acute in-field radiation dermatitis was associated with higher rate of late grade 2 to 4 skin fibrosis.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) (clinicaltrials.gov) - Jul 5, 2017
P2, N=23, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Grade 2 to 4 acute in-field radiation dermatitis was associated with higher rate of late grade 2 to 4 skin fibrosis. Trial primary completion date: Jun 2016 --> Jun 2018
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jul 4, 2017
P2, N=40, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Jun 2016 --> Jun 2018 Trial primary completion date: Feb 2017 --> Jun 2015
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Targeting the HER family with Pan-HER effectively overcomes resistance to cetuximab. (Pubmed Central) - Jul 1, 2017
Furthermore, intrinsically cetuximab-resistant HNSCC patient-derived xenograft tumors treated with Pan-HER exhibited significant growth delay compared to vehicle/cetuximab controls. These results suggest that targeting HER family receptors simultaneously with Pan-HER is a promising treatment strategy for tumors displaying intrinsic or acquired resistance to cetuximab.
- | Votrient (pazopanib) / Novartis, BeiGene, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Jun 27, 2017
P1, N=32, Active, not recruiting, Sponsor: Washington University School of Medicine
These results suggest that targeting HER family receptors simultaneously with Pan-HER is a promising treatment strategy for tumors displaying intrinsic or acquired resistance to cetuximab. Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Metastases: Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer (clinicaltrials.gov) - Jun 27, 2017
P1/2, N=90, Active, not recruiting, Sponsor: Western Regional Medical Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting